HRP20100620T1 - Kemijski in situ postupak sulfoniranja - Google Patents
Kemijski in situ postupak sulfoniranja Download PDFInfo
- Publication number
- HRP20100620T1 HRP20100620T1 HR20100620T HRP20100620T HRP20100620T1 HR P20100620 T1 HRP20100620 T1 HR P20100620T1 HR 20100620 T HR20100620 T HR 20100620T HR P20100620 T HRP20100620 T HR P20100620T HR P20100620 T1 HRP20100620 T1 HR P20100620T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- formula
- toluene
- products
- xylene
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 12
- 238000011065 in-situ storage Methods 0.000 title claims abstract 5
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims abstract 33
- 150000001875 compounds Chemical class 0.000 claims abstract 14
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims abstract 8
- 239000000203 mixture Substances 0.000 claims abstract 8
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims abstract 6
- 239000006227 byproduct Substances 0.000 claims abstract 6
- 239000008096 xylene Substances 0.000 claims abstract 6
- -1 sulfonate ester Chemical class 0.000 claims abstract 5
- 239000003638 chemical reducing agent Substances 0.000 claims abstract 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 claims abstract 4
- 230000001476 alcoholic effect Effects 0.000 claims abstract 3
- 239000003795 chemical substances by application Substances 0.000 claims abstract 3
- 238000006243 chemical reaction Methods 0.000 claims 3
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 claims 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical group CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 claims 2
- JEDZLBFUGJTJGQ-UHFFFAOYSA-N [Na].COCCO[AlH]OCCOC Chemical group [Na].COCCO[AlH]OCCOC JEDZLBFUGJTJGQ-UHFFFAOYSA-N 0.000 claims 2
- 239000002585 base Substances 0.000 claims 2
- 239000012419 sodium bis(2-methoxyethoxy)aluminum hydride Substances 0.000 claims 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical group C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- RUJPPJYDHHAEEK-UHFFFAOYSA-N ethyl piperidine-4-carboxylate Chemical compound CCOC(=O)C1CCNCC1 RUJPPJYDHHAEEK-UHFFFAOYSA-N 0.000 claims 1
- 239000012280 lithium aluminium hydride Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 239000000047 product Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Postupak za dobivanje spoja formule IIa: naznačen time da R je pogodan sulfonatni ester; iz (C1-C6)alkil-4-piperidinkarboksilatnog spoja prema formuli III: koji postupak sadrži slijedeće korake: (a) reakciju (C1-C6)alkil-4-piperidinkarboksilatnog spoja prema formuli III sa di-terc-butil dikarbonatom u prisutnosti toluena ili ksilena koji tvore prvu mješavinu koja sadrži toluen ili ksilen, terc-butanol i spoj prema formuli IV: (b) većinskog uklanjanja terc-butanola iz prve mješavine; (c) reakcije spoja prema formuli IV sa pogodnim sredstvom za redukciju in situ u prisutnosti toluena ili ksilena koji tvore drugu mješavinu koja sadrži toluen, redukcijske nus-produkte uključujući alkoholne nus-produkte i spoj prema formuli V: (d) većinskog uklanjanja alkoholnih nus-produkata iz druge mješavine; i (e) reakcije spoja prema formuli V sa pogodnim sredstvom za sulfoniranje in situ koji tvore sulfonatni ester u prisutnosti pogodne baze i toluena koji tvore spoj prema formuli IIa. Patent sadrži još 7 patentnih zahtjeva.
Claims (8)
1. Postupak za dobivanje spoja formule IIa:
[image]
naznačen time da R je pogodan sulfonatni ester;
iz (C1-C6)alkil-4-piperidinkarboksilatnog spoja prema formuli III:
[image]
koji postupak sadrži slijedeće korake:
(a) reakciju (C1-C6)alkil-4-piperidinkarboksilatnog spoja prema formuli III sa di-terc-butil dikarbonatom u prisutnosti toluena ili ksilena koji tvore prvu mješavinu koja sadrži toluen ili ksilen, terc-butanol i spoj prema formuli IV:
[image]
(b) većinskog uklanjanja terc-butanola iz prve mješavine;
(c) reakcije spoja prema formuli IV sa pogodnim sredstvom za redukciju in situ u prisutnosti toluena ili ksilena koji tvore drugu mješavinu koja sadrži toluen, redukcijske nus-produkte uključujući alkoholne nus-produkte i spoj prema formuli V:
[image]
(d) većinskog uklanjanja alkoholnih nus-produkata iz druge mješavine; i
(e) reakcije spoja prema formuli V sa pogodnim sredstvom za sulfoniranje in situ koji tvore sulfonatni ester u prisutnosti pogodne baze i toluena koji tvore spoj prema formuli IIa.
2. Postupak prema zahtjevu 1, naznačen time da spoj formule IIa je spoj formule II i sredstvo za sulfoniranje je tosil klorid
[image]
3. Postupak prema zahtjevu 1 ili 2, naznačen time da (C1-C6)alkil-4-piperidinkarboksilatni spoj prema formuli III je etil 4-piperidinkarboksilat.
4. Postupak prema zahtjevu 1 ili 2 ili 3, naznačen time da u koraku (c) sredstvo za redukciju je odabrano od natrij bis(2-metoksietoksi)aluminij hidrida, litij aluminij hidrida i diizobutilaluminij hidrida.
5. Postupak prema zahtjevu 4, naznačen time da u koraku (c) sredstvo za redukciju je natrij bis(2-metoksietoksi)aluminij hidrid.
6. Postupak prema bilo kojem ili više zahtjeva od 1 do 5, naznačen time da u koraku (e) baza je trietilendiamin.
7. Postupak prema bilo kojem ili više zahtjeva od 1 do 6, naznačen time da nadalje uključuje korak (f) izolacije spoja prema formuli IIa.
8. Postupak prema zahtjevu 7, naznačen time da korak (f) sadrži kristalizaciju uz korištenje sustava otapala toluena i izoheksana.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0519879.1A GB0519879D0 (en) | 2005-09-30 | 2005-09-30 | Chemical process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100620T1 true HRP20100620T1 (hr) | 2010-12-31 |
Family
ID=35395001
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100019T HRP20100019T1 (hr) | 2005-09-30 | 2010-01-11 | Kemijski postupak |
| HR20100620T HRP20100620T1 (hr) | 2005-09-30 | 2010-11-16 | Kemijski in situ postupak sulfoniranja |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100019T HRP20100019T1 (hr) | 2005-09-30 | 2010-01-11 | Kemijski postupak |
Country Status (32)
| Country | Link |
|---|---|
| US (8) | US8163926B2 (hr) |
| EP (2) | EP1943240B1 (hr) |
| JP (2) | JP5213715B2 (hr) |
| KR (1) | KR101307641B1 (hr) |
| CN (3) | CN101277948B (hr) |
| AR (1) | AR055671A1 (hr) |
| AT (2) | ATE481399T1 (hr) |
| AU (1) | AU2006296367B2 (hr) |
| BR (1) | BRPI0616715A2 (hr) |
| CA (2) | CA2745829C (hr) |
| CY (2) | CY1110275T1 (hr) |
| DE (2) | DE602006017004D1 (hr) |
| DK (2) | DK1943240T3 (hr) |
| ES (2) | ES2350513T3 (hr) |
| GB (1) | GB0519879D0 (hr) |
| HK (2) | HK1122553A1 (hr) |
| HR (2) | HRP20100019T1 (hr) |
| IL (2) | IL190172A (hr) |
| ME (2) | ME01466B (hr) |
| MY (2) | MY149834A (hr) |
| NO (1) | NO342152B1 (hr) |
| NZ (2) | NZ566566A (hr) |
| PL (2) | PL2053048T3 (hr) |
| PT (2) | PT1943240E (hr) |
| RS (2) | RS51515B (hr) |
| RU (1) | RU2448102C2 (hr) |
| SG (1) | SG165416A1 (hr) |
| SI (2) | SI2053048T1 (hr) |
| TW (2) | TWI424991B (hr) |
| UY (1) | UY29824A1 (hr) |
| WO (1) | WO2007036713A2 (hr) |
| ZA (1) | ZA200802416B (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7268230B2 (en) * | 2002-02-01 | 2007-09-11 | Astrazeneca Ab | Quinazoline compounds |
| GB0519879D0 (en) * | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
| CL2007003158A1 (es) * | 2006-11-02 | 2008-05-16 | Astrazeneca Ab | Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion. |
| EP2404595B1 (de) * | 2011-09-01 | 2015-08-05 | Symrise AG | Verfahren zur Herstellung von Indanon-Derivaten |
| US9273001B2 (en) * | 2012-08-15 | 2016-03-01 | Glaxo Group Limited | Chemical process |
| CN104098544A (zh) * | 2013-04-07 | 2014-10-15 | 浙江九洲药物科技有限公司 | 一种凡德他尼的制备方法 |
| CN106397401B (zh) * | 2016-08-30 | 2018-11-13 | 山东罗欣药业集团股份有限公司 | 一种抗癌药物的晶体化合物及其制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4870083A (en) * | 1987-11-24 | 1989-09-26 | Merrell Dow Pharmaceuticals Inc. | 1,4-Disubstituted-piperidinyl compounds useful as analgesics and muscle relaxants |
| JP2829744B2 (ja) | 1989-05-31 | 1998-12-02 | 川研ファインケミカル株式会社 | ピペリジンカルボン酸類の製造方法 |
| WO1992006086A1 (en) | 1990-10-01 | 1992-04-16 | Janssen Pharmaceutica N.V. | Novel 4-piperidinylcarbonyl derivatives |
| BR9205811A (pt) | 1991-03-28 | 1994-06-28 | Pfizer | Derivados heterociclicos de aminas ciclicas |
| CA2102780C (en) | 1991-05-10 | 2007-01-09 | Alfred P. Spada | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| WO1994019342A1 (en) | 1993-02-18 | 1994-09-01 | Kyowa Hakko Kogyo Co., Ltd. | Adenosine incorporation inhibitor |
| EP0700383B1 (en) | 1993-05-26 | 1998-09-23 | Syntex (U.S.A.) Inc. | Novel 1-phenylalkanone 5-ht 4? receptor ligands |
| DE4326344A1 (de) | 1993-08-05 | 1995-02-09 | Thomae Gmbh Dr K | Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| AU685212B2 (en) * | 1994-01-13 | 1998-01-15 | Merck Sharp & Dohme Limited | Gem-disubstituted azacyclic tachykinin antagonists |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| WO1997032856A1 (en) | 1996-03-05 | 1997-09-12 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| WO1998010767A2 (en) | 1996-09-13 | 1998-03-19 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
| GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| IL149034A0 (en) | 1999-11-05 | 2002-11-10 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors |
| GB0126879D0 (en) | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| EP1467995B1 (en) | 2001-12-20 | 2010-05-19 | OSI Pharmaceuticals, Inc. | Pyrrolopyrimidine a2b selective antagonist compounds, their synthesis and use |
| US7268230B2 (en) | 2002-02-01 | 2007-09-11 | Astrazeneca Ab | Quinazoline compounds |
| JP4389205B2 (ja) | 2002-02-06 | 2009-12-24 | 宇部興産株式会社 | ４−アミノキナゾリン化合物の製法 |
| JP2006502132A (ja) | 2002-08-09 | 2006-01-19 | アストラゼネカ アクチボラグ | 癌の治療における血管内皮細胞増殖因子受容体の阻害薬ｚｄ６４７４と放射線療法との併用 |
| GB0218526D0 (en) | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| GB0223380D0 (en) | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| CA2514227C (en) | 2003-02-13 | 2011-08-09 | Astrazeneca Ab | Combination therapy of zd6474 with 5-fu or/and cpt-11 |
| KR20060033782A (ko) | 2003-07-10 | 2006-04-19 | 아스트라제네카 아베 | 백금 화합물 및 임의적으로 이온화 방사능과 조합된퀴나졸린 유도체 ｚｄ6474의 혈관신생 및/또는 증가된 혈관투과성 관련 질환 치료 용도 |
| GB0318423D0 (en) | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| GB0519879D0 (en) * | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
-
2005
- 2005-09-30 GB GBGB0519879.1A patent/GB0519879D0/en not_active Ceased
-
2006
- 2006-09-27 RS RSP-2010/0520A patent/RS51515B/en unknown
- 2006-09-27 JP JP2008532864A patent/JP5213715B2/ja not_active Expired - Fee Related
- 2006-09-27 WO PCT/GB2006/003587 patent/WO2007036713A2/en active Application Filing
- 2006-09-27 DK DK06794582.4T patent/DK1943240T3/da active
- 2006-09-27 ME MEP-2013-21A patent/ME01466B/me unknown
- 2006-09-27 RS RSP-2010/0037A patent/RS51263B/sr unknown
- 2006-09-27 MY MYPI2011003076A patent/MY149834A/en unknown
- 2006-09-27 CA CA2745829A patent/CA2745829C/en not_active Expired - Fee Related
- 2006-09-27 PT PT06794582T patent/PT1943240E/pt unknown
- 2006-09-27 EP EP06794582A patent/EP1943240B1/en active Active
- 2006-09-27 SI SI200630816T patent/SI2053048T1/sl unknown
- 2006-09-27 CN CN200680036468XA patent/CN101277948B/zh active Active
- 2006-09-27 BR BRPI0616715-2A patent/BRPI0616715A2/pt not_active IP Right Cessation
- 2006-09-27 CA CA2624045A patent/CA2624045C/en not_active Expired - Fee Related
- 2006-09-27 SI SI200630524T patent/SI1943240T1/sl unknown
- 2006-09-27 CN CN201110159628.2A patent/CN102503933B/zh active Active
- 2006-09-27 PT PT09152654T patent/PT2053048E/pt unknown
- 2006-09-27 EP EP09152654A patent/EP2053048B8/en active Active
- 2006-09-27 AT AT09152654T patent/ATE481399T1/de active
- 2006-09-27 NZ NZ566566A patent/NZ566566A/en not_active IP Right Cessation
- 2006-09-27 US US12/088,680 patent/US8163926B2/en active Active
- 2006-09-27 DE DE602006017004T patent/DE602006017004D1/de active Active
- 2006-09-27 DK DK09152654.1T patent/DK2053048T3/da active
- 2006-09-27 AU AU2006296367A patent/AU2006296367B2/en not_active Ceased
- 2006-09-27 AT AT06794582T patent/ATE448218T1/de active
- 2006-09-27 RU RU2008116573/04A patent/RU2448102C2/ru not_active IP Right Cessation
- 2006-09-27 DE DE602006010428T patent/DE602006010428D1/de active Active
- 2006-09-27 SG SG201006940-9A patent/SG165416A1/en unknown
- 2006-09-27 ES ES09152654T patent/ES2350513T3/es active Active
- 2006-09-27 PL PL09152654T patent/PL2053048T3/pl unknown
- 2006-09-27 ES ES06794582T patent/ES2335435T3/es active Active
- 2006-09-27 CN CN201110159729.XA patent/CN102503898B/zh active Active
- 2006-09-27 PL PL06794582T patent/PL1943240T3/pl unknown
- 2006-09-27 ME MEP-2013-51A patent/ME01531B/me unknown
- 2006-09-27 KR KR1020087009317A patent/KR101307641B1/ko active IP Right Grant
- 2006-09-27 NZ NZ593930A patent/NZ593930A/xx not_active IP Right Cessation
- 2006-09-27 MY MYPI20080855A patent/MY145540A/en unknown
- 2006-09-29 AR ARP060104320A patent/AR055671A1/es not_active Application Discontinuation
- 2006-09-29 UY UY29824A patent/UY29824A1/es unknown
- 2006-09-29 TW TW099102690A patent/TWI424991B/zh not_active IP Right Cessation
- 2006-09-29 TW TW095136340A patent/TWI328580B/zh not_active IP Right Cessation
-
2008
- 2008-03-11 NO NO20081267A patent/NO342152B1/no not_active IP Right Cessation
- 2008-03-13 IL IL190172A patent/IL190172A/en not_active IP Right Cessation
- 2008-03-14 ZA ZA200802416A patent/ZA200802416B/xx unknown
- 2008-12-15 HK HK08113582.9A patent/HK1122553A1/xx not_active IP Right Cessation
-
2009
- 2009-09-21 HK HK09108619.5A patent/HK1130478A1/xx not_active IP Right Cessation
-
2010
- 2010-01-11 HR HR20100019T patent/HRP20100019T1/hr unknown
- 2010-01-25 CY CY20101100076T patent/CY1110275T1/el unknown
- 2010-11-12 CY CY20101101019T patent/CY1110887T1/el unknown
- 2010-11-16 HR HR20100620T patent/HRP20100620T1/hr unknown
-
2011
- 2011-12-07 US US13/314,034 patent/US8865899B2/en active Active
-
2012
- 2012-11-28 JP JP2012259782A patent/JP5654546B2/ja not_active Expired - Fee Related
-
2013
- 2013-07-21 IL IL227574A patent/IL227574A/en not_active IP Right Cessation
-
2014
- 2014-09-09 US US14/481,302 patent/US20140378684A1/en not_active Abandoned
-
2015
- 2015-07-22 US US14/805,816 patent/US9815816B2/en active Active
-
2017
- 2017-10-27 US US15/796,615 patent/US10344015B2/en active Active
-
2019
- 2019-05-08 US US16/406,246 patent/US20190263782A1/en not_active Abandoned
-
2020
- 2020-11-02 US US17/086,666 patent/US20220033377A1/en not_active Abandoned
-
2023
- 2023-03-07 US US18/118,549 patent/US20240150317A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100620T1 (hr) | Kemijski in situ postupak sulfoniranja | |
| RU2014143116A (ru) | Способы синтеза этилфумаратов и их применение в качестве промежуточных соединений | |
| US8981105B2 (en) | Process of preparing a thrombin specific inhibitor | |
| Vilaivan | A rate enhancement of tert-butoxycarbonylation of aromatic amines with Boc2O in alcoholic solvents | |
| EP2938616A1 (en) | The present invention relates to process for the preparation of tofacitinib and intermediates thereof. | |
| EP1253138A3 (en) | Novel tertiary amine compounds having an ester structure and processes for preparing same | |
| RU2007131535A (ru) | Получение замещенного хиноксалина высокой чистоты | |
| De Marco et al. | N-Alkylation of N-arylsulfonyl-α-amino acid methyl esters by trialkyloxonium tetrafluoroborates | |
| RS50663B (sr) | Postupci za dobijanje 3-o-zaštićenih morfinona i 3-o-zaštićenih morfinon dienol karboksilata | |
| WO2016074324A1 (zh) | 一种2-((4r,6s)-6-溴甲基-2,2-二甲基-1,3-二氧六环-4-基)乙酸酯的制备方法 | |
| CA2429563A1 (en) | Process for the preparation of donepezil | |
| US20160251316A1 (en) | Process for the preparation of enzalutamide | |
| RU2007112006A (ru) | Синтез бензоксазинона | |
| CA2647457A1 (en) | A hydride reduction process for preparing quinolone intermediates | |
| WO2014083571A1 (en) | A process for the preparation of alcaftadine | |
| RU2011141209A (ru) | Усовершенствованный способ получения ингибиторов дипептидиллептизады-iv и промежуточного соединения | |
| RU2007126972A (ru) | Способ получения n-замещенных салициламидов | |
| Ronsisvalle et al. | Substituted 1-phenyl-2-cyclopropylmethylamines with high affinity and selectivity for sigma sites | |
| RU2012118499A (ru) | Способ получения пиразинонового ингибитора тромбина и промежуточных соединений для его получения | |
| KR102593038B1 (ko) | 알킬아민 유도체의 제조 방법 및 이의 제조 중간체 | |
| JP6239751B2 (ja) | ラコサミドの製造方法 | |
| KR101162160B1 (ko) | 산 무수물 및/또는 산 할로겐화물 및 삼산화 황으로부터입체 장애 2급 아미노에터 알콜을 합성하는 방법 | |
| PE20060403A1 (es) | Procesos para la preparacion de esteres alquilicos o bencilicos del acido 2-ciano-3-naftalen-1-il-acrilico | |
| Cane-Honeysett et al. | A stereocontrolled route to protected isocyanates from alcohols | |
| JP2013010735A (ja) | １，２，４−トリアゾール化合物及びグアニジン誘導体の合成方法 |